A Phase 1/2 interventional study of MDX2001 in Biliary Tract Cancer, Breast Cancer and Cervical Cancer, sponsored by ModeX Therapeutics, An OPKO Health Company. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by ModeX Therapeutics, An OPKO Health Company (part of OPKO Health, Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Gallbladder Neoplasms with a site in United States — 16 open to participants now, 27 under way, 6 of them phase 3. Gallbladder Neoplasms · United States.
Among the 147 studies in Gallbladder Neoplasms with a site in United States, this one is the 10th largest by planned enrollment of the 127 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 1/2, reaches primary completion later than 17 of the 26 other live ones, and was the 136th registered.
301 studies on the registry are indexed under Gallbladder Neoplasms; 65 are open to participants now.
Browse Gallbladder Neoplasms studies →16 of the 147 studies in Gallbladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
J-Pharma Co., Ltd. · Sites in United States
Ages 18+
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Australia, Belgium and 16 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18–130
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Gallbladder Neoplasms studies recruiting now, 24 (56%) set no upper age limit and 8 (19%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 74 · Phase 3 15
First in 1994; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 330 is above the median of 56 across 222 interventional studies indexed under Gallbladder Neoplasms.
Median enrollment 44 across the 127 interventional studies, 102 across the 12 observational. Of the 112 that completed or were terminated, 45 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModeX Therapeutics, An OPKO Health Company, one of the names counted as OPKO Health, Inc.. Under that name alone:
ModeX Therapeutics, An OPKO Health Company is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
OPKO Health, Inc. has 1 study filed under Gallbladder Neoplasms — fewer than ten, so there is no comparison to draw.
7 of the studies in Gallbladder Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05506943Phase 3Compass TherapeuticsA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | 2027-08-31 |
| NCT07265674Phase 3J-Pharma Co., Ltd.A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | 2027-10 |
| NCT05000294University of FloridaAtezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT04907643Cedars-Sinai Medical CenterVirtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | 2027-03-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 147 studies in Gallbladder Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
This study consists of Phase 1a dose escalation, Phase 1b dose expansion in a single indication, and Phase 2a expansion in a single indication.
Primary Objectives
Secondary Objectives:
The expected duration of study intervention for patients may vary, based on progression date. The median expected duration of study per patient is estimated to be 10 months (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for long term follow-up).
301 studies on the registry are indexed under Gallbladder Neoplasms; 65 are open to participants now.
This study's planned enrollment of 330 is above the median of 56 across 222 interventional studies indexed under Gallbladder Neoplasms.
Browse Gallbladder Neoplasms studies →ModeX Therapeutics, An OPKO Health Company is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
First submitted after ModeX Therapeutics became part of OPKO Health, Inc..
Compared within Gallbladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Biliary Tract Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with metastatic solid tumors will receive MDX2001 as intravenous (IV) infusion or subcutaneous (SC) injection.
Drug: MDX2001
Patients with a single tumor indication receive MDX2001 as intravenous (IV) infusion or subcutaneous (SC) injection.
Drug: MDX2001
Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion or subcutaneous (SC) injection.
Drug: MDX2001
Patients with a single tumor indication will receive MDX2001 as intravenous (IV) infusion or subcutaneous (SC) injection at the recommended Phase 2 dose.
Drug: MDX2001
MDX2001 intravenous infusion or subcutaneous (SC) injection.
All Phases: Adverse events (AEs)
Incidence and severity of AEs and serious AEs (SAEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 including changes in clinical laboratory parameters
Time frame: Baseline until end of study, up to approximately 9 months
Phase 1b and Phase 2a: Objective response rate of MDX2001
Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
Phase 1: Recommended Phase 2 dose (RP2D)
Recommended Phase 2 dose is determined following the evaluation of MDX2001 safety including the incidences of dose limiting toxicities (DLTs), MDX2001 anti-tumor activity, and MDX2001 pharmacokinetics
Time frame: Baseline until end of study, up to approximately 9 months
Phase 1a: Objective response rate of MDX2001
Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per RECIST v1.1.
Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
All Phases: Duration of response (DOR)
Duration of response is defined as the time from first documentation of response (complete response \[CR\] or partial response \[PR\]) to documentation of objective disease progression or death due to any cause, whichever occurs first
Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
All Phases: Time to response (TTR)
Time to response is defined as the time from first dose to first documentation of response (CR or PR)
Time frame: From date of enrollment until the first documentation of response (CR or PR), approximately 4 months
All Phases: Disease control rate (DCR)
Disease control rate is defined as the proportion of evaluable patients with a best overall response (BOR) of stable disease, CR or PR
Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
All Phases: Progression free survival (PFS)
Progression-free survival is defined as the time from the first dose to the date of disease progression or death (any cause), whichever occurs first
Time frame: From date of enrollment until the end of treatment, up to approximately 6 months
All Phases: Pharmacokinetic Parameter Cmax of MDX2001
Maximum observed plasma concentration
Time frame: From date of enrollment until completion of the 6th cycle of treatment, up to approximately 6 months
All Phases: Pharmacokinetic parameter area under the curve (AUC(0-T)) of MDX2001
Area under the plasma concentration versus time curve
Time frame: From date of enrollment until the completion of the 3rd cycle of treatment, up to approximately 3 months
All Phases: Evaluation of MDX2001 immunogenicity
The presence and persistence of anti-MDX2001 antibodies
Time frame: Baseline until end of study, up to approximately 9 months
All Phases: Correlation between tumor antigen expression and anti-tumor activity of MDX2001
Relationship between H score cell surface target protein expression in tumor tissue at baseline and objective responses with MDX2001
Time frame: Baseline until the end of treatment, up to approximately 6 months
Plan to share: No
Started Jun 2024 (actual). Primary completion is estimated for Aug 2028, 50 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ModeX Therapeutics, An OPKO Health Company →